Company intelligence / Profile preview

Harris Vaccines

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Harris Vaccines was a biotechnology company specializing in the development and commercialization of rapidly deployable vaccines for the animal health industry. Utilizing its proprietary SirraVax RNA particle technology, the company focused on addressing emerging infectious diseases in livestock, most notably producing the first conditionally licensed vaccine for Porcine Epidemic Diarrhea virus (PEDv). The company's platform allowed for the rapid creation of herd-specific vaccines by inserting genetic sequences of specific pathogens into a standardized production system. In 2015, Harris Vaccines was acquired by Merck Animal Health, integrating its advanced vaccine technologies into Merck's global portfolio.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRNA-based drugs
Industry: Veterinary

Partnerships

Iowa State University

Beyond the preview

Go deeper on Harris Vaccines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harris Vaccines.